{"id":7952,"date":"2016-08-27T00:00:00","date_gmt":"2016-08-26T22:00:00","guid":{"rendered":"https:\/\/idibell.cat\/blog\/2016\/08\/27\/el-primer-test-epigenetic-per-identificar-els-tumors-dorigen-desconegut\/"},"modified":"2020-05-13T19:47:09","modified_gmt":"2020-05-13T17:47:09","slug":"el-primer-test-epigenetic-per-identificar-els-tumors-dorigen-desconegut","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2016\/08\/el-primer-test-epigenetic-per-identificar-els-tumors-dorigen-desconegut\/","title":{"rendered":"El primer test epigen\u00e8tic per identificar els tumors d\u2019origen desconegut"},"content":{"rendered":"<p><strong>El test EPICUP\u00ae \u00e9s una eina que ajuda a identificar fins al 87% dels casos de c\u00e0ncer d&#8217;origen desconegut (COD)<\/strong> En els pacients diagnosticats amb c\u00e0ncer, el m\u00e9s freq\u00fcent \u00e9s que es detecti el tumor primari o original i la pres\u00e8ncia o no de met\u00e0stasi, \u00e9s a dir, de c\u00e8l\u00b7lules del tumor original que s&#8217;han escapat del seu lloc de naixement i creixen en un altre teixit del pacient. No obstant aix\u00f2, entre un 5% i 10% dels tumors humans apareixen d&#8217;una altra manera: es diagnostica la met\u00e0stasi, per\u00f2 el tumor primari no es detecta tot i la realitzaci\u00f3 de diferents proves diagn\u00f2stiques. \u00c9s el que s&#8217;anomena C\u00e0ncer d&#8217;Origen Desconegut (COD) o per les sigles en angl\u00e8s, CUP (Cancer of Unknown Primary). Com que no se sap de quin tipus de tumor es tracta, la superviv\u00e8ncia d&#8217;aquests pacients \u00e9s molt limitada. <br \/> Avui, un article publicat a la revista <em>The Lancet Oncology<\/em>, la m\u00e9s prestigiosa en l&#8217;\u00e0rea d&#8217;Oncologia M\u00e8dica, pel Dr. Manel Esteller, director del Programa d&#8217;Epigen\u00e8tica i Biologia del C\u00e0ncer (PEBC) de l&#8217;Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL), Investigador ICREA i Professor de Gen\u00e8tica de la Universitat de Barcelona, \u200b\u200bmostra que \u00e9s possible emprar un test epigen\u00e8tic (anomenat EPICUP\u00ae) per descobrir a partir de quin tipus de tumor primari s&#8217;ha produ\u00eft la met\u00e0stasi en el pacient, la qual cosa permetr\u00e0 desenvolupar tractaments m\u00e9s espec\u00edfics. <br \/> &#8220;<em>Des de fa pocs anys, vam comen\u00e7ar a ser conscients que els patrons qu\u00edmics que regulen l&#8217;activitat dels gens, l&#8217;epigenoma, s\u00f3n espec\u00edfics per a cada teixit. Per exemple, s\u00f3n diferents en una c\u00e8l\u00b7lula del p\u00e0ncrees respecte a una c\u00e8l\u00b7lula del pulm\u00f3<\/em>&#8220;, comenta el Dr. Manel Esteller. &#8220;<em>Hem analitzat aquestes firmes epigen\u00e8tiques particulars per a cada tipus de c\u00e0ncer en m\u00e9s de 10.000 tumors humans. Quan ara estudiem l&#8217;ADN de la met\u00e0stasi d&#8217;un pacient amb tumor d&#8217;origen desconegut, amb la fotografia del seu epigenoma <\/em><em>que obtenim podrem dir que pertany a la fam\u00edlia del c\u00e0ncer de p\u00e0ncrees, de pulm\u00f3, de c\u00f2lon, de mama, etc. \u00c9s a dir, donem un diagn\u00f2stic de l&#8217;origen d&#8217;aquest tumor\u201d<\/em>. <\/p>\n<p>La identificaci\u00f3 del tipus de c\u00e0ncer mitjan\u00e7ant el test epigen\u00e8tic tindr\u00e0 un impacte significatiu en l\u2019elecci\u00f3 del tractament. &#8220;<em>Ara, aquest pacient no ser\u00e0 tractat a cegues, sin\u00f3 que podr\u00e0 rebre una ter\u00e0pia molt m\u00e9s espec\u00edfica per al seu tipus tumoral; <\/em><em>les dades inicials demostren que la superviv\u00e8ncia es dobla <\/em>&#8220;, explica el Dr. Esteller, i conclou sobre la investigaci\u00f3 a <em>The Lancet Oncology<\/em>: &#8220;<em>Una cosa molt important a tenir en compte \u00e9s que aquest no \u00e9s un descobriment a desenvolupar en els propers anys, sin\u00f3 que hem aconseguit que la prova es pugui aplicar des d\u2019avui mateix gr\u00e0cies a la col\u00b7laboraci\u00f3 amb laboratoris Ferrer<\/em>.&#8221; <strong><em><\/p>\n<p><\/em><\/strong> <strong>Article<\/strong>: <\/p>\n<p> Moran S, Mart\u00ednez-Card\u00fas A, Sayols S, Musul\u00e9n E, Balana C, Estival-Gonzalez A, Moutinho C, Heyn H, Diaz-Lagares A, Castro de Moura M, Stella GM, Comoglio PM, Ruiz-Mir\u00f3 M, Matias-Guiu X, Pazo-Cid R, Ant\u00f3n A, Lopez-Lopez R, Soler G, Longo F, Guerra I, Fernandez S, Assenov Y, Plass C, Morales R, Carles J, Bowtell D, Mileshkin L, Sia D, Tothill R, Tabernero J, Llovet JM, <strong><span style=\"text-decoration: underline;\">Esteller M<\/span><\/strong>. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. <strong><em>The Lancet Oncology<\/em><\/strong>, 16tlo0734, 2016.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>El test EPICUP\u00ae \u00e9s una eina que ajuda a identificar fins al 87% dels casos de c\u00e0ncer d&#8217;origen desconegut (COD)  Article Esteller M The Lancet Oncology<\/p>\n","protected":false},"author":6,"featured_media":7953,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-09 21:06:08","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7952"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=7952"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7952\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/7953"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=7952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=7952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=7952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}